의료기기 이야기

Background on battery regulationIn Europe, the Battery Regulation 2023/1542 was released in July 2023 with various deadlines to replace the Battery Directive 2006/66/EC. One fundamental aspect is that the legislation was promulgated as a Regulation and aligned to the New Legislative Framework (NLF). Recital 53 explained that this would help ensure “batteries are stored, used and discarded in a m..

Emergo에서 아래와 같이 웨비나를 개최한다.​▶ 주제: Japan Regulatory Requirements - Medical Device Software▶ 일시: 2024년 08월 08일 CST 9시 (한국시간: 08월 08일 23시) As the global market for medical device software (SaMD) expands, navigating the regulatory landscape becomes increasingly critical for manufacturers. While many regions share similar regulatory approaches, Japan presents unique challenges and opportunities. Our u..

Emergo by UL has been reporting on the landmark legislation that is the Artificial Intelligence Act (AIA). As the AIA was given the green light by EU institutions and the finish line is in sight, it seems fitting to conclude our regulatory series with a brief recap, as well as a focus on the high-risk AI systems on which the regulation is mainly concerned.RecapThe EU AIA  introduces a risk-based..

Global harmonization continues to excite us all. And, global harmonization of medical device registration submissions is one way to advance the objectives of the International Medical Device Regulators Forum (IMDRF) and regulatory reliance. These documents are a must-read for any serious regulatory professional. Here we elaborate on our regulatory update featured in April 2023.  Background on IM..

This is the third in our series of regulatory updates on the EU Artificial Intelligence Act (AIA). Since more than one month has passed since the law’s approval, we are providing this article ahead of the AIA’s publication in the Official Journal of European Union (OJEU). BackgroundOn May 21 2024, the EU AIA was approved and given the final green light by the EU Council. The AIA establishes requ..

The US Food and Drug Administration (FDA), Health Canada and UK MHRA (June 13) built on their 2021 guiding principles for good machine learning practice for medical device development by further identifying guiding principles for transparency for machine learning-enabled medical devices (MLMDs). As the healthcare sector continues to experience rapid proliferation of artificial intelligence (AI) ..

Emergo에서 아래와 같이 웨비나를 개최한다.​▶ 주제: Best Practices for Engaging with the US FDA on Human Factors Strategy▶ 일시: 2024년 07월 11일 EST 10시 (한국시간: 07월 11일 23시)  Engaging with the U.S. Food and Drug Administration (FDA) on your human factors engineering (HFE) strategy is an important step toward achieving a successful medical product submission and subsequent U.S. market access. In this webinar, the presen..

Regardless of a medical product’s complexity, manufacturers have many considerations when it comes to applying human factors during development. Applying human factors to a whole system of medical products versus a singular product might seem even more intimidating. Furthermore, additional complexities might emerge when applying human factors to a system of products where all products or compone..

Even three weeks after the 2024 Hospitalar conference in Brazil, it is still worth highlighting some important points raised by Marcella de Abreu, GEVIT/ANVISA Manager, during her presentation covering the RDC 830/2023 legislation for in vitro diagnostic devices. This also serves as a reminder that RDC 830/2023 now applies to IVDs and products within the scope of IVDs in Brazil.Background on RDC..

The New Zealand (NZ) Associate Minister of Health announced the intent to repeal the Therapeutic Products Act 2023 (TPA), which otherwise would come into force this year, with most provisions taking effect on September 1, 2026. On May 23, the Associate Minister also released a lightly redacted Cabinet paper and decision meeting minutes outlining the rationale behind the Ministry decision. Develo..